Avance Clinical North America: Proven Expertise With Global Solutions For US Biotechs
The success of a biotech drug development program often depends on the relationship it forms with its Clinical Research Organization (CRO) partner.
Avance Clinical, a global CRO with more than 3 decades of experience, has an impressive track record in the US with over 200 US studies including 140 in oncology.
Avance Clinical leverages partnerships with over 2,000 high-quality community-based sites and site networks to accelerate start-up timelines and patient recruitment. This approach significantly reduces the cost burden for biotechs.
A Relationship-Centric Model
Avance Clinical’s approach centers on building sponsor relationships from the earliest phases of clinical development and becoming a trusted partner throughout the clinical development lifecycle.
John Mann, Executive Vice President, North American Operations, explains: “Our goal is to create a relationship early and build on that relationship throughout the clinical development lifecycle. The insights gained from one Phase are critical in informing subsequent Phases. This continuity is something that many of our competitors simply don’t offer. The functional team leads that work on your early phase I studies are the same team leads that work on the later phase studies”
Therapeutic Expertise: Oncology, Central Nervous System (CNS), and Rare Disease
Oncology and CNS are key therapeutic areas that Avance Clinical can offer extensive experience -especially in the US.
John Mann emphasizes, “Our depth of knowledge in oncology, CNS, and rare disease allow us to design and execute trials with regulatory structure, data quality and accelerated timelines that support success.”
The Asia Advantage: A Strategic Solution for Later Phase US Biotechs
For US biotechs considering expansion to Asia, Avance Clinical’s GlobalReady model provides access to high-quality clinical trial destinations such as South Korea and Taiwan. These regions offer unique advantages, including world-class research facilities, competitive costs, and large patient pools for oncology and CNS trials.
Jessica Han, Director of Asian Operations, states: “The Asia Advantage offers US biotechs a strategic opportunity to accelerate their trials while accessing diverse patient populations and cutting-edge oncology expertise. South Korea and Taiwan, in particular, have become leading destinations for innovative trials.”
This integrated global strategy enables biotechs to extend their reach while ensuring consistent quality and efficiency across regions.
High-Touch, High-Value Partnerships
For US biotechs, partnering with a CRO that prioritizes flexibility, agility, and customer centricity is invaluable. Avance Clinical’s “A-Team” approach guarantees experienced, dedicated project teams accessible in US time zones. Clients benefit from consistent support, with leadership readily available, complemented by global teams in Australia, New Zealand, and Asia.
John Mann adds, “At Avance Clinical, you always get the A-Team. We believe in maintaining continuity, ensuring our clients have access to the best talent and insights at every stage of their trials. In the US, we have had only one person resign from the operations team in 18 months. In addition, you always have direct access to senior management at any time. That connectivity and support is available throughout the entire trial.”
This commitment to excellence has resulted in a 70% repeat customer rate, with many biotechs choosing to extend their partnerships with Avance Clinical from early to late phase trials.
Fast Start-Up and Strong Site Networks
Speed and site connectivity are critical to clinical trial success. Avance Clinical’s industry-leading start-up timelines are made possible through pre-negotiated master contracts with site networks who have access to over 2,000 sites, ensuring rapid activation and patient recruitment.
John Mann notes: “We understand that delays can be costly for biotechs. That’s why we prioritize efficiency without compromising quality, helping our clients get their trials off the ground quickly and effectively.”
Strong partnerships with both large institutions and community centers also ensure access to diverse patient populations, reducing recruitment challenges and enhancing trial success. Avance Clinical North America has partnerships with local community centers to enhance patient access and dramatically improve site activation timelines.
Why US Biotechs Partner with Avance Clinical
Avance Clinical stands out as the CRO of choice for US biotechs by delivering proven expertise in rare disease, oncology and CNS, seamless global trial execution, and the operational excellence needed to drive successful outcomes. With over 17 years of US experience, a track record of 200+ US studies, and partnerships with 2,000+ sites, Avance Clinical ensures rapid start-up timelines and robust patient recruitment.
The company’s “A-Team” approach guarantees biotechs dedicated, experienced project teams available in US time zones, supported by the GlobalReady strategy for integrated global coverage, including the Asia Advantage in South Korea and Taiwan. Avance Clinical is more than a service provider—it's a trusted partner committed to advancing biotech innovations.